Scilex Holding Company announced that it has filed a New Drug Submission (NDS) to Health Canada?s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +3.60% | +40.54% | -43.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.63% | 139M | |
+9.28% | 8.74B | |
-14.24% | 4.94B | |
+49.95% | 4.7B | |
+5.96% | 3.98B | |
-23.57% | 2.28B | |
+15.78% | 2.28B | |
+17.77% | 2.14B | |
-32.28% | 2.12B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada